What is the target price for Regeneron Pharmaceuticals (regn) stock?
18 brokers have issued 1 year target prices for Regeneron Pharmaceuticals' shares. Their predictions range from $320.00 to $480.00. On average, they expect Regeneron Pharmaceuticals' stock price to reach $385.38 in the next year.
Does REGON Pharmaceuticals stock pay a dividend?
Regeneron Pharmaceuticals does not currently pay a dividend. Regeneron Pharmaceuticals does not have a long track record of dividend growth. In the past three months, Regeneron Pharmaceuticals insiders have sold more of their company's stock than they have bought.
What is the price targets for regn?
The high price target for REGN is $453.00 and the low price target for REGN is $320.00. There are currently 11 hold ratings, 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."
Where can I buy regn shares?
Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
See more
Is REGN stock a buy?
Out of 15 analysts, 5 (33.33%) are recommending REGN as a Strong Buy, 5 (33.33%) are recommending REGN as a Buy, 3 (20%) are recommending REGN as a Hold, 2 (13.33%) are recommending REGN as a Sell, and 0 (0%) are recommending REGN as a Strong Sell. What is REGN's earnings growth forecast for 2022-2024?
Is Regeneron Pharmaceuticals a buy?
IBD 50 Stocks To Watch: Biotech Regeneron Remains In Buy Zone As Market Waffles. Biotech stock Regeneron Pharmaceuticals (REGN) is in a field that continues to receive investor love while the overall stock market sputters and plays havoc with tech stocks.
What is price of Regeneron on NYSE today?
$ 594.59CloseChgChg %$594.59-1.14-0.19%
Who makes Regeneron stock?
Top 10 Owners of Regeneron Pharmaceuticals IncStockholderStakeShares ownedWellington Management Co. LLP2.68%2,890,203Loomis, Sayles & Co. LP2.36%2,548,047Dodge & Cox2.07%2,237,063Geode Capital Management LLC1.94%2,092,7716 more rows
Will REGN stock go up?
Stock Price Forecast The 22 analysts offering 12-month price forecasts for Regeneron Pharmaceuticals Inc have a median target of 684.00, with a high estimate of 790.00 and a low estimate of 536.00. The median estimate represents a +15.07% increase from the last price of 594.42.
Is REGN a buy Zacks?
See rankings and related performance below. The VGM Score are a complementary set of indicators to use alongside the Zacks Rank....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy24.75%2Buy18.15%3Hold9.70%4Sell5.35%2 more rows
What is the meaning of REGN?
regn n. (countable and uncountable) rain.
Who is the CEO of Regeneron?
Leonard Schleifer (1988–)Regeneron Pharmaceuticals / CEOLeonard S. Schleifer is the co-founder and chief executive of the biotechnology company Regeneron Pharmaceuticals. Wikipedia
Will Regeneron pay a dividend?
Does Regeneron pay a cash dividend? No, we have never paid a cash dividend nor do we expect to pay any dividends in the foreseeable future.
How do I invest in Renergen?
How to buy Renergen Group SharesOpen a FREE Trading Account here.Verify account via email or phone number.Set up 2FA (Two Factor Authentication)KYC your profile to get verified.Explore and get acquainted with the trading dashboard.Deposit fiat into your trading account.More items...
Who are the major stockholders in Regeneron?
Largest shareholders include Fmr Llc, BlackRock Inc., Vanguard Group Inc, Capital World Investors, State Street Corp, Jpmorgan Chase & Co, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Wellington Management Group Llp, Loomis Sayles & Co L P, and AGTHX - GROWTH FUND OF AMERICA Class A.
Should I buy or sell Regeneron Pharmaceuticals stock right now?
19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last twelve months. There are currently...
What is Regeneron Pharmaceuticals' stock price forecast for 2022?
19 analysts have issued 1 year price targets for Regeneron Pharmaceuticals' shares. Their forecasts range from $536.00 to $844.00. On average, they...
How has Regeneron Pharmaceuticals' stock price performed in 2022?
Regeneron Pharmaceuticals' stock was trading at $631.52 on January 1st, 2022. Since then, REGN shares have decreased by 9.5% and is now trading at...
When is Regeneron Pharmaceuticals' next earnings date?
Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecas...
How were Regeneron Pharmaceuticals' earnings last quarter?
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced its earnings results on Wednesday, May, 4th. The biopharmaceutical company reported $11.49...
Who are Regeneron Pharmaceuticals' key executives?
Regeneron Pharmaceuticals' management team includes the following people: Dr. Leonard S. Schleifer M.D. , Ph.D., Founder, Pres, CEO & Director (...
What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?
423 employees have rated Regeneron Pharmaceuticals CEO Leonard S. Schleifer on Glassdoor.com . Leonard S. Schleifer has an approval rating of 87%...
Who are some of Regeneron Pharmaceuticals' key competitors?
Some companies that are related to Regeneron Pharmaceuticals include Amgen (AMGN) , Gilead Sciences (GILD) , Vertex Pharmaceuticals (VRTX) , Bi...
What other stocks do shareholders of Regeneron Pharmaceuticals own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NV...
When will Regeneron release its earnings?
When did Regeneron buy back its stock?
Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021. View our earnings forecast for Regeneron Pharmaceuticals.
When is Regeneron earnings call?
Regeneron Pharmaceuticals declared that its board has initiated a stock buyback program on Tuesday, November 5th 2019 , which allows the company to buyback $1,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to purchase up to 2.9% of its shares through open market purchases.
How much does Regeneron make?
Regeneron Pharmaceuticals will be holding an earnings conference call on Thursday, August 5th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.
What is Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals has a market capitalization of $62.47 billion and generates $8.50 billion in revenue each year. The biopharmaceutical company earns $3.51 billion in net income (profit) each year or $28.66 on an earnings per share basis.
Does market cap include convertible securities?
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products including: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; and Kevzara in rheumatoid arthri
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target and Consensus Rating
It does not include securities convertible into the common equity securities. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable).
Analyst Ratings By Month
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).
Average Share Price and Price Target by Month
The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Regeneron Pharmaceuticals (NASDAQ:REGN) Analyst Ratings Frequently Asked Questions
The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target.